Diabetes mellitus remains one of the most prevalent chronic diseases worldwide and is projected by the World Health Organization to become the seventh leading cause of mortality by 2030. In efforts to enhance therapeutic strategies for diabetes, mineral-based compounds are being explored for their supportive benefits. This study investigates the potential effects of the novel mineral formulation Dibeston on renal excretory function in a model of alloxan-induced diabetes. The experimental design involved 40 white laboratory rats assigned to five groups: Group 1: healthy controls; Group 2: alloxan-induced diabetes (untreated controls); Group 3: alloxan-induced diabetes treated with Dibeston; Group 4: alloxan-induced diabetes treated with Asparkam; and Group 5: alloxan-induced diabetes treated with a selenium-based preparation. Key renal parameters, including blood glucose, serum creatinine, urine output (polyuria), and urinary protein levels (proteinuria), were measured. The findings indicate that Dibeston significantly improves renal function in alloxan-induced diabetic nephropathy, suggesting its potential as an adjunct in diabetes management.
Eurasian Academy of Medicine and Dentistry